http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013149800-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2012-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013149800-A |
| titleOfInvention | 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidine-7 (8H) -they for the treatment of disorders of the nerve system and cancer |
| abstract | 1. A compound selected from the group consisting of: and its pharmaceutically acceptable salts. A compound according to claim 129, selected from the group consisting of: and its pharmaceutically acceptable salts. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, carrier or binder. A method of treating a subject suffering from a CNS disorder or cancer, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 or 2 or a composition according to claim 3.5. The method of claim 4, wherein the CNS disorder is schizophrenia, Alzheimer's disease, mild cognitive impairment, autism, autism spectrum disorder, fragile X-chromosome syndrome, Rett syndrome, Asperger syndrome, Angelman syndrome, bipolar disorder and depression. The method of claim 4, wherein the cancer is selected from ovarian cancer, breast cancer, colon cancer, brain cancer, chronic myeloid leukemia, renal cell carcinoma, stomach cancer, leukemia, lung cancer, melanoma, prostate cancer, T-cell lymphoma, hepatocellular cancer, bladder cancer, kidney cancer, glioblastoma, mesothelioma, neuroma, meningioma, neuroblastoma, medulloblastoma, peripheral perineural malignant tumor, ependymoma, craniopharyngioma, astrocytoma, germinoma, gli we mixed glioma tumor horioidnogo plexus, oligodendrogliomas, peripheral neuroectodermal tumors, primitive neuroectodermal tumor (PNET), lymphoma, central nervous system, pituitary adenomas, schwannomas, head and neck cancer and cancer of the esophagus, cancer of the esophagus, not |
| priorityDate | 2011-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.